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Abstract
Background: Osteoporosis-related fractures are a significant public health concern. Interventions that increase
detection and treatment of osteoporosis, as well as prevention of fractures and falls, are substantially underutilized. This
paper outlines the protocol for a pragmatic randomised trial of a multifaceted community-based care program aimed at
optimizing the evidence-based management of falls and fractures in patients at risk.
Design: 6-month randomised controlled study.
Methods: This population-based study was completed in the Algoma District of Ontario, Canada a geographically vast
area with Sault Ste Marie (population 78 000) as its main city. Eligible patients were allocated to an immediate intervention
protocol (IP) group, or a delayed intervention protocol (DP) group. The DP group received usual care for 6 months and
then was crossed over to receive the interventions. Components of the intervention were directed at the physicians and
their patients and included patient-specific recommendations for osteoporosis therapy as outlined by the clinical practice
guidelines developed by Osteoporosis Canada, and falls risk assessment and treatment. Two primary outcomes were
measured including implementation of appropriate osteoporosis and falls risk management. Secondary outcomes
included quality of life and the number of falls, fractures, and hospital admissions over a twelve-month period. The patient
is the unit of allocation and analysis. Analyses will be performed on an intention to treat basis.
Discussion: This paper outlines the protocol for a pragmatic randomised trial of a multi-faceted, community-based
intervention to optimize the implementation of evidence based management for patients at risk for falls and osteoporosis.
Trial Registration: This trial has been registered with clinicaltrials.gov (ID: NCT00465387)
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Osteoporosis, a chronic condition characterized by
decreased bone mass and increased risk of fractures, is a
significant public health concern. It affects over 200 mil-
lion people worldwide[1], an estimated 10 million people
in the US[2], 4 million people in the UK[3] and 1.4 mil-
lion people in Canada[2,4]. Fragility fractures are the clin-
ical consequence of osteoporosis. While vertebral
fractures can cause back pain, loss of height and disability,
hip fractures have a more significant impact on quality of
life leading to loss of function, and admission to long-
term care. [5-9] It is estimated that 1 in 5 people who suf-
fer a hip fracture will die during the first year and less than
one third gain their pre-fracture level of function. [2]
Moreover, the economic impact of this condition is con-
siderable, with the total acute care cost of osteoporosis
estimated to be over $1.3 billion per year in Canada[9],
$20 billion in the US[10] and over 30 billion in Europe.
[11,12] Given that the proportion of people aged 65 and
older is increasing, this will likely lead to an even more
significant burden of disease. [4,12]
Osteoporosis increases the risk of fractures in elderly
patients who fall. [4] Falls are the leading cause of acci-
dental death among people aged 65 years of age and
older, and also account for significant morbidity, includ-
ing fracture, impaired mobility, decreased quality of life
due to fear of falling, depression, admission to long-term
care facilities, and death. [13-18] Estimates vary, but
approximately 20% of falls among the elderly result in
serious injury requiring medical attention, and 2% to
10% of these falls result in fractures. [13,14,18-21]
Because of the morbidity and mortality associated with
falls, they result in marked costs for the health care system
and are a major health concern. [22]
For the prevention of fractures, a substantial body of evi-
dence supports detection and treatment of osteoporosis in
high-risk patients, including appropriate bone mineral
density testing and therapy with calcium, vitamin D, and
drugs that decrease bone resorption or increase bone for-
mation. [23] For example, bisphosphonates reduce the
risk of future osteoporosis-related fracture by 40 to 60%,
with fracture reduction apparent within a year of starting
treatment. [23] Similarly, research suggests that interven-
tions targeting both intrinsic and environmental risk fac-
tors reduce the risk of falls in older people. [24]
Despite the incorporation of this evidence from rand-
omized trials into clinical practice guidelines, these inter-
ventions are considerably underutilized. [25-29]
According to a recent systematic review, the proportion of
individuals with a fragility fracture who received a diag-
nostic test for osteoporosis or a diagnosis from a physician
ranged from 1.7% to 50%. [27] And, it is unclear how
many patients who experience a fracture are assessed for
risk of falls.
These care gaps highlight the finding that additional effort
is needed to ensure that appropriate knowledge transla-
tion is achieved to optimize management of patients at
risk for falls and fracture. This study was designed to help
fill this knowledge to practice gap. The primary objective
of this study was to determine if a multicomponent, com-
plex, community-based, integrated care strategy could
optimize the evidence-based and guideline-concordant
management of people at high risk for falls and fractures.
This study was developed by a community partnership
because of a locally identified need to address these evi-
dence to practice gaps. Given the significant disease bur-
den of falls and fractures in the local community, the
partnership decided to implement and evaluate a multi-
faceted intervention to enhance care.
Methods
Between March 2003 and January 2006, we conducted a
randomized trial of a multifaceted community based
intervention to optimize care of patients at risk for falls
and fractures. Two parallel trials were conducted in this
group of patients. We did not conduct a factorial trial
because we had no reason to believe that osteoporosis
treatment and falls assessment would not be managed
independently. Previous studies have shown this to be
true. [30,31] An economics evaluation was carried out in
parallel to this randomized controlled trial to evaluate the
costs and consequences as well as cost-effectiveness of
applying the intervention.
Setting and Study Population
This study was completed in the Algoma District of
Ontario, Canada, a geographically vast area with Sault Ste
Marie (population 78 000) as its main city. The study rep-
resented a partnership among consumers, providers and
other stakeholders interested in reducing falls and frac-
tures in the community. It was conducted by the Group
Health Centre (GHC), a multidisciplinary, multi-spe-
cialty, not-for-profit health service community centre, in
partnership with Sault Area Hospital (SAH), a facility with
250 active beds. When the study was initiated, the Group
Health Centre had 44 000 registered patients. Distin-
guishing features of the GHC are multiple types of health
care professionals integrated within a health care delivery
system, capitation funding and an electronic medical
record system (EMR). The study was also completed in
partnership with the Algoma Community Care Access
Centre; the Algoma Health Unit; and the Slips, Trips and
Falls Committee of Sault Ste Marie Safe Communities
Partnership, a community-based falls prevention coali-
tion.Page 2 of 6
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were community-dwelling, aged 55 years or older, able to
give informed consent, and were identified to be at risk for
a future fracture according to one of the following criteria:
1. attended the hospital Fracture Clinic for a non-patho-
logical fracture of the vertebrae, hip or wrist or BMD in the
past year with a T-score of ≤ -2.0;
2. attended the hospital Emergency Department with a
fall and found to be at high risk for falls as defined by a
Timed Up and Go[32] result of greater than 14 seconds;
or,
3. were self-referred or referred by a health care provider
because of perceived high risk of fracture, and identified as
a high risk for falls defined by a Timed Up and Go result
of greater than 14 seconds.
Patients were excluded if they were already receiving
appropriate therapy for osteoporosis as outlined in the
Osteoporosis Canada guidelines. [23]
Interventions
Osteoporosis Risk Assessment and Management
This intervention was multifaceted and consisted of pro-
viding evidence-based management strategies for oste-
oporosis to both the patients and their primary care
providers. Following randomization, a bone mineral den-
sity (BMD) test was facilitated for participants if it had not
been done within the past year, and the results were sent
to the primary care physician along with relevant prescrib-
ing information based on the Osteoporosis Canada guide-
lines. [13] A complete list of the patient's medications was
compiled from two sources and provided to physicians:
(1) the patient's pharmacy records; and (2) home visits
conducted by the study nurses. Medications associated
with increased risk of fracture were identified, and physi-
cians were asked to assess this list of flagged medications
(Appendix).
Patients received personalized counseling from the
research nurse about osteoporosis, including a written
summary of the proposed management plan. They also
received educational materials on calcium and vitamin D,
risk factors for osteoporosis, and their BMD results. For
those few individuals without a primary care physician,
the same materials were provided but patients were
encouraged to visit a walk-in clinic or the emergency
department.
Falls assessment and management
The intervention was multifaceted and consisted of pro-
viding patient-specific evidence-based recommendations
targeted to reduce falls risk to both the patients and their
primary care providers. A research nurse assessed partici-
pants in their home and completed the Berg Balance
Scale[33], the InterRAI Screener[34,35], a medication
review and an assessment for orthostatic hypotension.
The InterRai screener is used to assess the elderly individ-
ual to identify those who merit further assessment in
order to prevent or stabilise early functional or health
decline. Medications associated with increased risk of falls
were identified through review of pharmacy records and
home visits and primary care providers were asked to
assess this list of flagged medications (Appendix).
The criteria for appropriate referral for physiotherapy and
occupational therapy services were based on the results of
the InterRAI Screener and the Berg Balance Score. Physio-
therapy interventions were tailored to each patient and
included strengthening exercises, gait and balance train-
ing, and referral to activities such as T'ai Chi classes. Occu-
pational therapy interventions were also tailored to each
patient and included home environmental assessment
and cognitive testing. Details on the interventions pro-
vided by the rehabilitation therapists will be described in
additional detail in the results paper for this study. All
therapists completed standard reporting forms indicating
their recommended interventions and barriers to patient
compliance with these recommendations.
Patients received personalized counseling from the
research nurse about fall prevention including a written
summary of the suggested management plan. They also
received educational materials including a checklist for
falls prevention.
Allocation and Blinding
Eligible patients were randomized using a computer gen-
erated randomization scheme under supervision of the
study biostatistician, into an immediate intervention pro-
tocol (IP) group or to a delayed intervention protocol
(DP) group. All members of the DP group received usual
health care during the first 6 months of the main study
and then were able to receive the intervention after this
period. Patients, physicians and outcomes assessors could
not be blinded to the fact that patients were part of a falls
and fracture prevention study. All patients were followed-
up at 6 and 12 months after the completion of the initial
assessment.
Outcomes and Data Collection
The primary outcome for the osteoporosis study was
appropriate osteoporosis management based on the 2002
clinical practice guidelines for osteoporosis in Canada.
[23] This was the most current evidence-based guideline
available for use at the time of study onset and was gener-
ally consistent with US and UK guidelines. The primary
outcome for the falls study was the implementation ofPage 3 of 6
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ments of outcomes were obtained through patient records
(obtained through the Electronic Medical Record), thera-
pists' reports, and pharmacy data. A standardized chart
review of the Electronic Medical Record was the primary
source of data for both groups.
Secondary outcomes included the number of falls and
fractures as recorded in monthly patient diaries. Follow-
up telephone calls every 3 months were used to obtain
this data and completed patient diaries were mailed to the
investigators at study end. Quality of life was measured
using the OPTQoL[36], a disease-specific quality of life
questionnaire. After the main study was completed at 6-
months, and the DP group crossed-over to receive the
intervention, all patients were followed up for a further 6
months.
Economics substudy
The costs that will be included are: nursing time, adminis-
trative time (e.g. booking appointments), home visit
travel, costs of health care professional continuing educa-
tion, costs of community education, and the costs of pro-
gram materials. Interviews with program staff and cost
information from the GHC administration will be used to
calculate program costs. Research project evaluation costs
will be excluded from program costs. Costs to the health
care system as well as costs to the patient will be collected
from the GHC electronic medical record, the Sault Area
Hospital medical record, or via patient interview. The
intervention program costs and health resource utiliza-
tion were collected at 6 months post-enrollment, 1 year
post-enrollment and 2 years post-enrollment. Analyses
will be done from the perspectives of the public payer and
the patient. Effectiveness and cost information will be
applied to a decision analytic model that has been specif-
ically designed to determine the cost effectiveness of vari-
ous treatments for osteoporosis. To assess the long term
cost-effectiveness of the program for both men and
women of various ages, separate long term projection
models for both men and women by age would be
required. The only model that is currently available is a
model based on post-menopausal osteoporosis. [37,38]
Therefore, it is in this patient population that the long
term cost-effectiveness will be estimated based on the
intermediate outcomes from this study.
Qualitative substudy
A sample of program staff, patients and physicians will be
interviewed about their experiences in the study and to
explore issues around costs, adherence to the intervention
and whether the material on osteoporosis and falls pre-
vention was discussed by patients and physicians. Individ-
ual, semi-structured interviews will be facilitated by an
experienced interviewer. Purposive sampling will be used
to identify patients who did and did not receive appropri-
ate therapy. Their primary care physicians will also be
invited to participate in individual interviews. Domains of
enquiry will focus on knowledge of osteoporosis and falls
prevention information and perceptions of use of this evi-
dence in decision making and clinical care. Barriers and
facilitators to implementation will also be explored. Inter-
views will be audiotaped and the tapes will be transcribed.
Any unique participant identifiers will be removed from
the transcripts. Two investigators will independently anal-
ysis the transcripts using content analysis to identify
themes. NVivo will be used to analyse the data. Investiga-
tors will use the constant comparative method to chal-
lenge the development of their themes and will use
memos to track the development of their themes and ana-
lytical strategy.
Sample size and Analysis
Local pilot data suggested that 40% of people would
receive appropriate osteoporosis medications at 6
months. Similarly, it was anticipated that 40% of people
would receive appropriate falls assessment at 6 months.
We determined a minimal clinically important difference
of 20% and with a two-tailed alpha of 0.05, power of 0.80,
the patient as the unit of allocation and analysis, and
assuming a loss to follow-up of 10%, a total sample size
of 200 patients was needed.
Descriptive statistics will be calculated for all variables of
interest. Continuous measures will be summarized using
means and standard deviations and categorical measures
will be summarized using percentages. The principal out-
come measure will be assessed using a two sample two-
sided test of proportions and will be performed on an
intention to treat basis.
Ethics approval was received from the Joint Group Health
Centre/Sault Area Hospital Research and Ethics Board.
This trial has been registered with clinicaltrials.gov (ID:
NCT00465387)
Discussion
It is critical that the health care community address the
deficiencies that exist with respect to knowledge transla-
tion and management of osteoporosis given the signifi-
cant burden of disease associated with falls and fractures.
Implementing evidence-based strategies with timely fol-
low-up and treatment is especially important in acute-care
settings (e.g. fracture clinics and hospitals), since the indi-
viduals who present in these settings are often at highest
risk for future sequelae. [39,40] The study will be able to
evaluate the clinical and cost impact of a multidisciplinary
intervention program for falls risk and osteoporosis man-
agement on appropriate assessment and treatment com-
pared to usual care in a northern community. Its design isPage 4 of 6
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is evaluated before a decision is made to implement it
long-term. The combination of clinical and cost evidence
generated is essential information for health care decision
makers assessing the long term viability of the program.
Limitations of this trial include that randomization will
occur at the level of the patient rather than at the practice
level and a short follow up time of 6 to 12 months.
Because of the small number of primary care practices in
this location, we are unable to randomize at the practice
level. Given that that it is extremely difficult to change
behaviour[41], and that there are significant time con-
straints to the primary care visits in this region due to phy-
sician shortages, we anticipate that this will not have a
significant impact on the study outcomes.
The findings from this trial will provide information of
interest to many stakeholders including patients, health
care managers, public health officials, policy makers, and
health care professionals amongst others. To our knowl-
edge, it represents the first Canadian trial attempting to
bridge the evidence-to-practice gap around osteoporosis
and falls prevention. Moreover, it includes a successful
partnership amongst relevant community stakeholder
groups which is required to ensure appropriate imple-
mentation of a multi-faceted intervention and to facilitate
sustainability of effective interventions.
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Appendix: risk medications 
Medications associated with an increased risk of falls:
1. Benzodiazepines: alprazolam, midazolam, clonazepam,
delavirdine, diazepam, halazepam, lorazepam, chlo-
rdiazepoxide, oxazepam, prazepam, quazepam,
temazepam, triazolam.
2. Tricyclic Antidepressants: amitriptyline (Elavil),
amoxaine (Asendin), clomipramine (Anafranil)
desipramine (Norpramin), dothiepin (Prothiaden), dox-
epin (Sinequan), imipramine (Tofranil), nortriptyline
(Aventyl), trimipramine (Surmontil), lofepramine
(Gamanil).
3. Direct-Acting Vasodilators: doxazosin (Cardura), hytrin
(Terazosin)
Medications associated with an increased risk of oste-
oporosis:
1. Glucocorticoids: Cortef, cortisone, dexamethasone,
hydrocortisone, prednisone, betamethasone, fludrocorti-
sone, methylprednisone, prednisolone, tramcinolone.
2. Inhaled Corticosteroids: beclomethasone, budesonide,
fluticasone, flunisolide, tramcinolone.
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